Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2025-01-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2024-0916.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045408394346496 |
|---|---|
| author | Young Eun Chon Dong Yun Kim Hong Jae Chon Do Young Kim |
| author_facet | Young Eun Chon Dong Yun Kim Hong Jae Chon Do Young Kim |
| author_sort | Young Eun Chon |
| collection | DOAJ |
| format | Article |
| id | doaj-art-1542cda331a042f28f78f62ab1564e1a |
| institution | DOAJ |
| issn | 2287-2728 2287-285X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj-art-1542cda331a042f28f78f62ab1564e1a2025-08-20T02:54:42ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2025-01-01311e98e10010.3350/cmh.2024.09162075Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”Young Eun Chon0Dong Yun Kim1Hong Jae Chon2Do Young Kim3 Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Korea Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Koreahttp://e-cmh.org/upload/pdf/cmh-2024-0916.pdfsorafeniblenvatinibhepatocellular carcinoma |
| spellingShingle | Young Eun Chon Dong Yun Kim Hong Jae Chon Do Young Kim Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study” Clinical and Molecular Hepatology sorafenib lenvatinib hepatocellular carcinoma |
| title | Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study” |
| title_full | Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study” |
| title_fullStr | Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study” |
| title_full_unstemmed | Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study” |
| title_short | Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study” |
| title_sort | correspondence to letter to the editor on sorafenib vs lenvatinib in advanced hepatocellular carcinoma after atezolizumab bevacizumab failure a real world study |
| topic | sorafenib lenvatinib hepatocellular carcinoma |
| url | http://e-cmh.org/upload/pdf/cmh-2024-0916.pdf |
| work_keys_str_mv | AT youngeunchon correspondencetolettertotheeditoronsorafenibvslenvatinibinadvancedhepatocellularcarcinomaafteratezolizumabbevacizumabfailurearealworldstudy AT dongyunkim correspondencetolettertotheeditoronsorafenibvslenvatinibinadvancedhepatocellularcarcinomaafteratezolizumabbevacizumabfailurearealworldstudy AT hongjaechon correspondencetolettertotheeditoronsorafenibvslenvatinibinadvancedhepatocellularcarcinomaafteratezolizumabbevacizumabfailurearealworldstudy AT doyoungkim correspondencetolettertotheeditoronsorafenibvslenvatinibinadvancedhepatocellularcarcinomaafteratezolizumabbevacizumabfailurearealworldstudy |